BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31832803)

  • 21. Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial.
    Zanoni L; Broccoli A; Lambertini A; Pellegrini C; Stefoni V; Lodi F; Fonti C; Nanni C; Zinzani PL; Fanti S
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1661-1671. PubMed ID: 31102000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic Tumor Burden Assessed by Dual Time Point [
    Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A
    Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [¹⁸F]fluorothymidine-positron emission tomography in patients with locally advanced breast cancer under bevacizumab treatment: usefulness of different quantitative methods of tumor proliferation.
    Marti-Climent JM; Dominguez-Prado I; Garcia-Velloso MJ; Boni V; Peñuelas I; Toledo I; Richter JA
    Rev Esp Med Nucl Imagen Mol; 2014; 33(5):280-5. PubMed ID: 25066253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual-Tracer Assessment of Dynamic Changes in Reoxygenation and Proliferation Decrease During Fractionated Radiotherapy in Murine Tumors.
    Yu W; Su X; Zhang D; Qiao F; Wang H; Jiang J; Xu H
    Front Oncol; 2020; 10():1046. PubMed ID: 32766135
    [No Abstract]   [Full Text] [Related]  

  • 25. 18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging.
    Zhou M; Wang C; Hu S; Zhang Y; Yao Z; Li J; Guo W; Zhang Y
    Nucl Med Commun; 2013 Jul; 34(7):694-700. PubMed ID: 23604223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in (18)F-fluorothymidine and (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with head and neck cancer treated with chemoradiotherapy.
    Hoshikawa H; Mori T; Kishino T; Yamamoto Y; Inamoto R; Akiyama K; Mori N; Nishiyama Y
    Ann Nucl Med; 2013 May; 27(4):363-70. PubMed ID: 23378102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
    Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
    J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.
    Kostakoglu L; Duan F; Idowu MO; Jolles PR; Bear HD; Muzi M; Cormack J; Muzi JP; Pryma DA; Specht JM; Hovanessian-Larsen L; Miliziano J; Mallett S; Shields AF; Mankoff DA;
    J Nucl Med; 2015 Nov; 56(11):1681-9. PubMed ID: 26359256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the diagnostic value of 3-deoxy-3-18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study.
    Han D; Yu J; Zhong X; Fu Z; Mu D; Zhang B; Xu G; Yang W; Zhao S
    Dis Esophagus; 2012 Jul; 25(5):416-26. PubMed ID: 21951837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study.
    Smyczek-Gargya B; Fersis N; Dittmann H; Vogel U; Reischl G; Machulla HJ; Wallwiener D; Bares R; Dohmen BM
    Eur J Nucl Med Mol Imaging; 2004 May; 31(5):720-4. PubMed ID: 14991243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mismatched intratumoral distribution of [
    Wang X; He Y; Zhou W; Bai X; Wu Y; Wang X; Li XF
    Oncol Lett; 2017 Nov; 14(5):5279-5284. PubMed ID: 29098026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of colorectal cancer using ¹⁸F-FLT PET: comparison with ¹⁸F-FDG PET.
    Yamamoto Y; Kameyama R; Izuishi K; Takebayashi R; Hagiike M; Asakura M; Haba R; Nishiyama Y
    Nucl Med Commun; 2009 Nov; 30(11):841-5. PubMed ID: 19773672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual time point fluorodeoxyglucose positron emission tomography/computed tomography in differentiation between malignant and benign lesions in cancer patients. Does it always work?
    Saleh Farghaly HR; Mohamed Sayed MH; Nasr HA; Abdelaziz Maklad AM
    Indian J Nucl Med; 2015; 30(4):314-9. PubMed ID: 26430314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined
    Sachpekidis C; Goldschmidt H; Kopka K; Kopp-Schneider A; Dimitrakopoulou-Strauss A
    EJNMMI Res; 2018 Apr; 8(1):28. PubMed ID: 29633046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma.
    Nishiyama Y; Yamamoto Y; Fukunaga K; Kimura N; Miki A; Sasakawa Y; Wakabayashi H; Satoh K; Ohkawa M
    J Nucl Med; 2006 Apr; 47(4):633-8. PubMed ID: 16595497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
    Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
    Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
    Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
    Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer.
    Been LB; Hoekstra HJ; Suurmeijer AJ; Jager PL; van der Laan BF; Elsinga PH
    Oral Oncol; 2009 Dec; 45(12):e211-5. PubMed ID: 19692292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imaging proliferation in human leukemia-tumor bearing mice with (18)F-FLT: Comparison with (18)F-FDG PET.
    Lu L; Jiang L; Guan H; Gao Y; Lu H
    Hell J Nucl Med; 2012; 15(3):206-9. PubMed ID: 23106052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.